Skip to content
MARKETS / NASDAQ / BFRG
NASDAQ · PHARMACEUTICAL PREPARATIONS

BullFrog AI Holdings, Inc. BFRG

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$116,670
$-6.5M
In brief

What this company does

Our platform technology, bfLEAP™, is an analytical AI/ML platform derived from technology developed at The Johns Hopkins University Applied Physics Laboratory (“JHU-APL”), which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The Company’s principal business address is 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878.

Written from the business description in BullFrog AI Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.

Growth
USD 116,670.00
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.1 · Net income -6.5
-2.5M-5.0M20212022202320242025
Compound annual growth
+126.8%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−5570 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -5652.4% · Net -5569.6%
-10000%-20000%20212022202320242025
ROE
FY2025 · ROE -183.0%
-50%-100%-150%20212022202320242025

Each USD of equity lost 183 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks

Total assetsUSD 2.8M
EquityUSD 2.1M
CashUSD 2.2M
Current ratio3.85×

Equity funds 76% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021
Revenue $B0.0·0.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0·
Income tax $B·····
Net income $B−0.0−0.0−0.0−0.0−0.0
Free cash flow $B···−0.0·
EPS, diluted $−0.63−0.85−0.89−0.70·
Dividend / sh $·····
Payout %·····
ROE %−183.0−185.1···
Shares out B0.010.010.010.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 23 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 72 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021

Share this section

Download image